報價延遲最少15分鐘:2025/12/22 04:53 EST
盤前時段
|
||||
|
0.125 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.125
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.10/-0.29
|
|
企業價值
20.22M
|
| 資產負債 |
|
每股賬面淨值
-0.00
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
455.00K
|
|
每股收益
0.07
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy. |
